Bioactive Materials (Jul 2022)

Mitochondrial temperature-responsive drug delivery reverses drug resistance in lung cancer

  • Lifo Ruan,
  • Jun Chen,
  • Chuanchao Du,
  • Huiru Lu,
  • Jiayu Zhang,
  • Xiaomeng Cai,
  • Rui Dou,
  • Wenchu Lin,
  • Zhifang Chai,
  • Guangjun Nie,
  • Yi Hu

Journal volume & issue
Vol. 13
pp. 191 – 199

Abstract

Read online

Reversal of cancer drug resistance remains a critical challenge in chemotherapy. Mitochondria-targeted drug delivery has been suggested to mitigate drug resistance in cancer. To overcome the intrinsic limitations in conventional mitochondrial targeting strategies, we develop mitochondrial temperature-responsive drug delivery to reverse doxorubicin (DOX) resistance in lung cancer. Results demonstrate that the thermoresponsive nanocarrier can prevent DOX efflux and facilitate DOX accumulation and mitochondrial targeting in DOX-resistant tumors. As a consequence, thermoresponsive nanocarrier enhances the cytotoxicity of DOX and reverses the drug resistance in tumor-bearing mice. This work represents the first example of mitochondrial temperature-responsive drug delivery for reversing cancer drug resistance.

Keywords